Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IRWD Ironwood Pharmaceuticals	$0.65 -5.1%	$1.10	$0.59 ▼ $7.11	$105.01M	0.37	2.52 million shs	2.43 million shs
MYGN Myriad Genetics	$3.84 -6.6%	$7.97	$3.83 ▼ $29.30	$353.96M	2.01	1.10 million shs	3.51 million shs
VSTM Verastem	$7.13 -4.4%	$6.40	$2.10 ▼ $13.52	$367.12M	0.85	1.10 million shs	2.24 million shs
ZBIO Zenas Biopharma	$8.68 -4.5%	$8.86	$5.83 ▼ $26.25	$363.12M	N/A	187,579 shs	97,506 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IRWD Ironwood Pharmaceuticals	-5.14%	-18.06%	+0.17%	-67.71%	-90.21%
MYGN Myriad Genetics	-6.57%	-9.88%	-52.48%	-73.79%	-84.86%
VSTM Verastem	-4.42%	+6.64%	+49.16%	+16.69%	-45.82%
ZBIO Zenas Biopharma	-4.51%	-0.23%	+2.12%	+867,999,900.00%	+867,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
IRWD Ironwood Pharmaceuticals	4.5242 of 5 stars	4.1	4.0	0.0	3.4	1.8	0.8	1.9
MYGN Myriad Genetics	4.0937 of 5 stars	4.1	2.0	0.0	4.1	1.7	1.7	0.6
VSTM Verastem	3.1856 of 5 stars	4.5	1.0	0.0	0.0	3.0	2.5	0.6
ZBIO Zenas Biopharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IRWD Ironwood Pharmaceuticals	2.13	Hold	$4.78	637.03% Upside
MYGN Myriad Genetics	2.12	Hold	$16.04	317.60% Upside
VSTM Verastem	3.00	Buy	$14.33	101.03% Upside
ZBIO Zenas Biopharma	3.00	Buy	$40.00	360.83% Upside

Current Analyst Ratings Breakdown

Latest IRWD, ZBIO, MYGN, and VSTM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/9/2025	VSTM Verastem	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$10.00 ➝ $14.00
5/8/2025	MYGN Myriad Genetics	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Peer Perform
5/7/2025	MYGN Myriad Genetics	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$18.00
5/7/2025	MYGN Myriad Genetics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$14.00 ➝ $8.00
5/7/2025	MYGN Myriad Genetics	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$19.00 ➝ $10.00
5/7/2025	MYGN Myriad Genetics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$16.00 ➝ $7.00
5/7/2025	MYGN Myriad Genetics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Equal Weight	$22.00 ➝ $6.00
4/17/2025	MYGN Myriad Genetics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$18.00 ➝ $14.00
4/16/2025	IRWD Ironwood Pharmaceuticals	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
4/15/2025	IRWD Ironwood Pharmaceuticals	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Equal Weight	$7.00 ➝ $1.00
4/15/2025	IRWD Ironwood Pharmaceuticals	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold	$8.00 ➝ $0.70

(Data available from 5/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IRWD Ironwood Pharmaceuticals	$317.68M	0.33	N/A	N/A	($2.21) per share	-0.29
MYGN Myriad Genetics	$837.60M	0.42	N/A	N/A	$9.53 per share	0.40
VSTM Verastem	$10M	36.71	N/A	N/A	$2.27 per share	3.14
ZBIO Zenas Biopharma	$5M	72.62	N/A	N/A	N/A	∞

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IRWD Ironwood Pharmaceuticals	-$1.00B	-$0.20	N/A	2.60	N/A	-0.65%	-0.96%	0.74%	N/A
MYGN Myriad Genetics	-$263.30M	-$1.12	N/A	N/A	N/A	-14.09%	-4.51%	-3.07%	N/A
VSTM Verastem	-$87.37M	-$3.50	N/A	N/A	N/A	N/A	-332.73%	-73.97%	5/15/2025 (Estimated)
ZBIO Zenas Biopharma	N/A	-$3.55	N/A	∞	N/A	N/A	N/A	N/A	N/A

Latest IRWD, ZBIO, MYGN, and VSTM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	VSTM Verastem	-$0.72	-$0.96	-$0.24	-$0.96	$0.10 million	N/A
5/7/2025	Q1 2025	IRWD Ironwood Pharmaceuticals	-$0.05	-$0.14	-$0.09	-$0.23	$67.02 million	$41.14 million
5/6/2025	Q1 2025	MYGN Myriad Genetics	-$0.05	-$0.03	+$0.02	N/A	$200.37 million	$195.90 million
3/20/2025	Q4 2024	VSTM Verastem	-$0.76	-$1.33	-$0.57	-$1.33	$0.15 million	N/A
2/27/2025	Q4 2024	IRWD Ironwood Pharmaceuticals	$0.10	$0.02	-$0.08	$0.02	$93.85 million	$90.55 million
2/25/2025	Q4 2024	MYGN Myriad Genetics	$0.03	-$0.09	-$0.12	-$0.47	$210.35 million	$210.60 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
IRWD Ironwood Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
MYGN Myriad Genetics	N/A	N/A	N/A	N/A	N/A
VSTM Verastem	N/A	N/A	N/A	N/A	N/A
ZBIO Zenas Biopharma	$0.05	0.55%	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IRWD Ironwood Pharmaceuticals	N/A	3.62	3.62
MYGN Myriad Genetics	0.05	1.90	1.73
VSTM Verastem	2.77	3.23	3.23
ZBIO Zenas Biopharma	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
IRWD Ironwood Pharmaceuticals	N/A
MYGN Myriad Genetics	99.02%
VSTM Verastem	88.37%
ZBIO Zenas Biopharma	N/A

Insider Ownership

Company	Insider Ownership
IRWD Ironwood Pharmaceuticals	12.90%
MYGN Myriad Genetics	2.40%
VSTM Verastem	2.10%
ZBIO Zenas Biopharma	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
IRWD Ironwood Pharmaceuticals	220	161.81 million	139.38 million	Optionable
MYGN Myriad Genetics	2,600	92.18 million	89.12 million	Optionable
VSTM Verastem	50	51.49 million	43.53 million	Optionable
ZBIO Zenas Biopharma	N/A	41.83 million	N/A	N/A

IRWD, ZBIO, MYGN, and VSTM Headlines

Recent News About These Companies

ZBIO LAWSUIT ALERT: Levi & Korsinsky Notifies Zenas BioPharma, Inc. Investors – Lead Plaintiff Deadline June 16, 2025

May 14 at 9:20 PM | accessnewswire.com

Zenas BioPharma, Inc. (ZBIO) Class Action Lawsuit: Levi & Korsinsky Reminds Investors of June 16, 2025 Deadline

May 14 at 4:30 PM | accessnewswire.com

ZBIO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Zenas BioPharma, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

May 14 at 4:00 PM | globenewswire.com

Contact Levi & Korsinsky by June 16, 2025 to Join Class Action Against Zenas BioPharma, Inc. (ZBIO)

May 14 at 3:30 PM | accessnewswire.com

ROSEN, SKILLED INVESTOR COUNSEL, Encourages Zenas BioPharma, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - ZBIO

May 14 at 3:21 PM | accessnewswire.com

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zenas BioPharma

May 14 at 3:06 PM | globenewswire.com

Securities Class Action Lawsuit Filed Against Zenas BioPharma, Inc. (ZBIO) - Levi & Korsinsky Represents Shareholders

May 14 at 9:15 AM | accessnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Zenas BioPharma, Inc. of Class Action Lawsuit and Upcoming Deadlines - ZBIO

May 14 at 9:00 AM | accessnewswire.com

Join Class Action to Recover Losses from Zenas BioPharma, Inc. (ZBIO) - Contact Levi & Korsinsky Before June 16, 2025

May 14 at 7:15 AM | accessnewswire.com

ZBIO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Zenas BioPharma, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit!

May 14 at 7:00 AM | accessnewswire.com

Zenas BioPharma, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before June 16, 2025 to Discuss Your Rights - ZBIO

May 13 at 9:30 PM | accessnewswire.com

Class Action Filed Against Zenas BioPharma, Inc. (ZBIO) - June 16, 2025 Deadline to Join - Contact Levi & Korsinsky

May 13 at 8:30 PM | accessnewswire.com

Levi & Korsinsky Reminds Zenas BioPharma, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of June 16, 2025 - ZBIO

May 13 at 5:00 PM | accessnewswire.com

Zenas BioPharma Investors: Cohen Milstein Highlights June 16 Deadline to Seek Lead Plaintiff Role in Securities Lawsuit

May 13 at 4:33 PM | globenewswire.com

Shareholders of Zenas BioPharma, Inc. Should Contact Levi & Korsinsky Before June 16, 2025 to Discuss Your Rights - ZBIO

May 13 at 4:00 PM | accessnewswire.com

ROSEN, NATIONAL TRIAL COUNSEL, Encourages Zenas BioPharma, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - ZBIO

May 13 at 3:15 PM | accessnewswire.com

Shareholders of Zenas BioPharma, Inc. Should Contact Levi & Korsinsky Before June 16, 2025 to Discuss Your Rights – ZBIO

May 13 at 12:51 PM | globenewswire.com

Class Action Filed Against Zenas BioPharma, Inc. (ZBIO) - June 16, 2025 Deadline to Join - Contact Levi & Korsinsky

May 13 at 9:15 AM | accessnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Zenas BioPharma, Inc. of Class Action Lawsuit and Upcoming Deadlines - ZBIO

May 13 at 9:00 AM | globenewswire.com

Investors in Zenas BioPharma, Inc. Should Contact Levi & Korsinsky Before June 16, 2025 to Discuss Your Rights - ZBIO

May 13 at 7:30 AM | accessnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IRWD, ZBIO, MYGN, and VSTM Company Descriptions

Ironwood Pharmaceuticals NASDAQ:IRWD

$0.65 -0.04 (-5.14%)

As of 05/14/2025 04:00 PM Eastern

Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; Apraglutide, a next-generation, long-acting synthetic peptide analog of glucagon-like peptide-2, as a differentiated therapeutic for rare diseases, including short bowel syndrome dependent on parenteral support and acute graft versus host disease; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.

Myriad Genetics NASDAQ:MYGN

$3.84 -0.27 (-6.57%)

As of 05/14/2025 04:00 PM Eastern

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions. It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, and Onsite Women's Health. Myriad Genetics, Inc. was incorporated in 1992 and is headquartered in Salt Lake City, Utah.

Verastem NASDAQ:VSTM

$7.13 -0.33 (-4.42%)

As of 05/14/2025 04:00 PM Eastern

Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers. Verastem, Inc. was incorporated in 2010 and is headquartered in Needham, Massachusetts.

Zenas Biopharma NASDAQ:ZBIO

$8.68 -0.41 (-4.51%)

As of 05/14/2025 04:00 PM Eastern

Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company. The firm is mainly engaged in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time